MYC
MYC (Myc proto-oncogene protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Skin cancer, Multiple myeloma and 5 more.
Overview
Transcription factor that binds DNA in a non-specific manner, yet also specifically recognises the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis.
CIViC holds 12 clinical evidence items and 0 assertions across 4 variants, naming Capmatinib, Olaparib, Pazopanib and Ganetespib and others. Open Targets scores its association with cancer at 0.74 (direct and indirect evidence; datatypes affected pathway 0.83, literature 1.00, genetic association 0.65, somatic mutation 0.81, animal model 0.52). IntOGen calls it a driver in 4 cohorts (2 activating, 2 loss-of-function), covering Acute Myeloid Leukaemia, Burkitt Lymphoma, Malignant Lymphoma, Non-Hodgkin Lymphoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · MYC (Myc proto-oncogene protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Skin cancer, Multiple myeloma and 5 more.
- 1 · What it is
MYC (Myc proto-oncogene protein) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor, a biomarker and a fusion partner, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Skin cancer, Multiple myeloma and 5 more.
- 2 · What goes wrong in cancer
Transcription factor that binds DNA in a non-specific manner, yet also specifically recognises the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes.
- 3 · How drugs use it
No product in this corpus aims at MYC yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:7553 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P01106 (protein name, function text, keywords and locations (REST API)); CIViC gene MYC (12 evidence items, 0 assertions, 4 variants; diseases: Lung Adenocarcinoma, Diffuse Large B-cell Lymphoma, Multiple Myeloma, Oesophageal Carcinoma, Oesophagus Squamous Cell Carcinoma and 5 more (GraphQL API, CC0)); Open Targets ENSG00000136997 (association with cancer (MONDO_0004992) 0.74; per-cancer scores at or above 0.5: prostate cancer 0.55, urinary bladder cancer 0.59, acute lymphoblastic leukaemia 0.53, diffuse large B-cell lymphoma 0.59, non-Hodgkin lymphoma 0.77, skin cancer 0.60 (GraphQL API, CC0)); IntOGen MYC (driver in 4 cohorts (Act 2, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcription factor that binds DNA in a non-specific manner, yet also specifically recognises the core sequence 5'-CAC[GA]TG-3'. Activates the transcription of growth-related genes. Binds to the VEGFA promoter, promoting VEGFA production and subsequent sprouting angiogenesis. Regulator of somatic reprogramming, controls self-renewal of embryonic stem cells. Functions with TAF6L to activate target gene expression through RNA polymerase II pause release. Positively regulates transcription of HNRNPA1, HNRNPA2 and PTBP1 which in turn regulate splicing of pyruvate kinase PKM by binding repressively to sequences flanking PKM exon 9, inhibiting exon 9 inclusion and resulting in exon 10 inclusion and production of the PKM M2 isoform. Location: Nucleus, nucleoplasm; Nucleus, nucleolus; Nucleus; Cytoplasm (UniProt). Locus 8q24.21 (HGNC).
- Non-Hodgkin lymphoma: Open Targets association 0.77 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL)
- Skin cancer: Open Targets association 0.60 with skin cancer (MONDO_0002898)
- Multiple myeloma: CIViC evidence names this disease
- Oesophageal cancer: CIViC evidence names this disease
- Bladder & urothelial cancer: Open Targets association 0.59 with urinary bladder cancer (MONDO_0001187)
- Leukaemia: Open Targets association 0.56 with leukaemia (MONDO_0005059)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 9 therapies; IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 12 clinical evidence items on its variants; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: High-grade B-cell Lymphoma, With MYC And BCL2 Rearrangements.
Latest papers
topQuery for this target: (TITLE:"MYC" OR ABSTRACT:"MYC" OR TITLE:"MYC proto-oncogene, bHLH transcription factor" OR ABSTRACT:"MYC proto-oncogene, bHLH transcription factor" OR TITLE:"Myc proto-oncogene protein" OR ABSTRACT:"Myc proto-oncogene protein" OR TITLE:"c-Myc" OR ABSTRACT:"c-Myc" OR TITLE:"bHLHe39" OR ABSTRACT:"bHLHe39") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MYC, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetRB1
Shares Bladder cancer (KEGG map), Small cell lung cancer (KEGG map), Skin cancer (all types), Oesophageal cancer.
- TargetCREBBP
Shares Leukaemia (all types), Oesophageal cancer, Non-Hodgkin lymphoma (all types), Bladder & urothelial cancer.
- TargetNSD2
Shares Leukaemia (all types), Non-Hodgkin lymphoma (all types), Bladder & urothelial cancer, Breast cancer (all types).
- TargetPAX5
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).
- TargetEPS15
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).
- TargetTERT
Shares Leukaemia (all types), Skin cancer (all types), Bladder & urothelial cancer, Breast cancer (all types).
- TargetCDKN2A
Shares Bladder cancer (KEGG map), Leukaemia (all types), Skin cancer (all types), Oesophageal cancer.
- TargetSUZ12
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).